Revolution Medicines’ (RVMD.O), which opens a new tab,  ‌helped patients with pancreatic cancer live nearly twice as long as those treated with chemotherapy in a keenly anticipated late-stage trial, sending its shares surging 40%.

Patients who received the once-daily pill, ​daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 ​months for those on chemotherapy, the standard of care. The pancreatic cancer community has declared that they wanted a revolution in a disease that has just a 13% survival rate five years after diagnosis.

Today, Revolution Medicines delivered results that could very well change their world with a doubling of survival in an advanced form of the disease.

Revolution’s daraxonrasib improved progression-free survival and overall survival in the Phase 3 RASolute 302 trial that featured previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to a Monday morning release.

Daraxonrasib achieved an overall survival of 13.2 months, compared with 6.7 months with chemotherapy. While the data come from an interim analysis of the late-stage trial, Revolution has declared them final, given the results and will now move to file for approval with regulatory agencies, including the FDA.

“These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” Revolution CEO Mark Goldsmith said in a statement. He promised that the company is now “moving with urgency” to get the drug in for regulatory review around the world.

Revolution was granted a Commissioner’s National Priority Voucher for the asset in October 2025, which aims to accelerate the approval of certain medicines as selected by the FDA commissioner. The program speeds the approval process from 10-12 months to just one or two.

(ref-reuters.com)